Nevro Corp. Stock
Your prediction
Pros and Cons of Nevro Corp. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Nevro Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Nevro Corp. | - | - | - | - | - | - | - |
| Orthofix Medical Inc. | 4.520% | 4.188% | 18.452% | 6.417% | -22.868% | -43.143% | -69.665% |
| Lantheus Holdings Inc | -0.340% | -3.618% | -10.031% | 44.098% | 53.671% | 31.626% | - |
| Cerus Corp. | 0.540% | -27.519% | -32.734% | 66.075% | 6.735% | -15.955% | -56.713% |
Comments
Nevro Corp. (NYSE: NVRO) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $5.85 price target on the stock, down previously from $6.00.
Show more
Ratings data for NVRO provided by MarketBeat
Nevro Corp. (NYSE: NVRO) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. They now have a $4.00 price target on the stock, down previously from $9.00.
Show more
Ratings data for NVRO provided by MarketBeat
Nevro Corp. (NYSE: NVRO) had its price target lowered by analysts at Piper Sandler from $7.00 to $6.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for NVRO provided by MarketBeat
News
Globus Medical Q1 Earnings Call Highlights
Globus Medical (NYSE:GMED) reported a strong start to 2026, with first-quarter revenue and earnings rising sharply as the company cited continued momentum in U.S. spine, margin expansion and
